



Commercial/Healthcare Exchange PA Criteria

Effective: August 11th, 2022

Prior Authorization: Camzyos

Products Affected: Camzyos™ (mavacamten) oral capsules

Medication Description: Camzyos is an allosteric and reversible inhibitor selective for cardiac myosin. It modulates the number of myosin heads that cross-bridge to actin during systole or diastole. Excess myosin actin cross-bridge formation and dysregulation of the super-relaxed state are mechanistic hallmarks of hypertrophic cardiomyopathy (HCM). Mavacamten promotes an energy-sparing, recruitable, super-relaxed state. In HCM patients, this reduces dynamic left ventricular outflow tract obstruction and improves cardiac filling pressures.

Covered Uses: Treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

Exclusion Criteria: None

Required Medical Information:

1. Diagnosis

Prescriber Restriction: Prescribed by a cardiologist

Age Restriction: 18 years of age or older

Coverage Duration: Initial: 8 months Renewal: 12 months

Other Criteria:

Initial Approval Criteria

1. **Obstructive Hypertrophic Cardiomyopathy.** Approve for 8 months if patient meets the following criteria:

A. Patient meets both of the following (i **and** ii):

- i. Patient has at least one symptom associated with obstructive hypertrophic cardiomyopathy; **AND**
Note: Examples of symptoms include shortness of breath, chest pain, lightheadedness, fainting, fatigue, and reduced ability to perform physical exercise
- ii. Patient has New York Heart Association Class II or III symptoms of heart failure; **AND**
Note: Class II signifies mild symptoms with moderate physical activity and some exercise limitations whereas Class III denotes noticeable symptoms with minimal physical activity and patients are only comfortable at rest.

B. Patient with left ventricular hypertrophy meets one of the following (i **or** ii):

- i. Patient has maximal left ventricular wall thickness ≥ 15 mm; **OR**

August 2022



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Page 1 of 3

- ii. Patient has familial hypertrophic cardiomyopathy with a maximal left ventricular wall thickness ≥ 13 mm;
AND
- C. Patient has a peak left ventricular outflow tract gradient ≥ 50 mmHg (at rest or after provocation [Valsalva maneuver or post exercise]); **AND**
- D. Patient has a left ventricular ejection fraction of $\geq 55\%$

Renewal Criteria

1. **Obstructive Hypertrophic Cardiomyopathy** Approve for 1 year if the patient meets ALL of the following criteria
 - A. Patient has been established on therapy for at least 8 months; **AND**
Note: A patient who has received < 8 months of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy)
 - B. Patient meets both of the following (i **and** ii):
 - i. Currently or prior to starting therapy, patient has or has experienced at least one symptom associated with obstructive hypertrophic cardiomyopathy **AND**
Note: Examples of symptoms include shortness of breath, chest pain, lightheadedness, fainting, fatigue, and reduced ability to perform physical exercise.
 - ii. Currently or prior to starting therapy, patient is in or was in New York Heart Association Class II or III heart failure; **AND**
Note: Class II signifies mild symptoms with moderate physical activity and some exercise limitations whereas Class III denotes noticeable symptoms with minimal physical activity and patients are only comfortable at rest.
 - C. Patient has a current left ventricular ejection fraction of $\geq 50\%$; **AND**
 - D. Patient meets at least one of the following (i **or** ii):
 - i. Patient experienced a beneficial clinical response when assessed by at least one objective measure; **OR**
Note: Examples include improved peak oxygen consumption/mixed venous oxygen tension; decreases in left ventricular outflow tract gradient; reductions in N-terminal pro-B-type natriuretic peptide levels; decreased high-sensitivity cardiac troponin I levels; reduced ventricular mass index; and/or a reduction in maximum left atrial volume index.
 - ii. Patient experienced stabilization or improvement in at least one symptom related to obstructive hypertrophic cardiomyopathy
Note: Examples of symptoms include shortness of breath, chest pain, lightheadedness, fainting, fatigue, ability to perform physical exercise, and/or favorable changes in the Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23) Clinical Summary Score (CSS) or Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Shortness of Breath domain scores.

References:

1. Camzyos™ capsules [prescribing information]. Brisbane, CA; MyoKardia/Bristol Myers Squibb; April 2022.

Policy Revision history

August 2022





Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	8/11/2022

August 2022